If you’re not too familiar with cancer research then you’re probably unaware of some very talented individuals. The fight against cancer is at an all-time high and there have been many advanced breakthroughs over the past 16 years. Many of the medications currently used today are much more effective than medications of the past. Seattle Genetics is one of the leaders when it comes to advanced breakthrough therapies. The organization has well 800 employees, been ranked by Forbes as one of the fastest growing companies in the nation, and it produces some of the very best cancer fighting drugs. With any great company/business, there has to be great leadership and Seattle Genetics is no exception.
Clay Siegall is the man of the hour and he’s doing everything in his power to eradicate the world of this deadly disease. He’s a man of many talents because of his broad educational background. He’s known by many as a philanthropist, doctor, scientist, guest speaker, and author. Dr. Siegall has been in the game for many years and has worked with many of the biggest names in cancer research such as The National Institute of Health, The National Cancer Institute, and Bristol Myers Squibb. Dr. Siegall studied at George Washington University and received a Ph.D in Genetics. He also studied at The University of Maryland where he received a (BS) in Zoology. As you can see, the guy is clearly in a class of his own. Being the President, CEO, and a Founder of Seattle Genetics, Dr. Siegall has built a strong structure to work from. He implements his three main functions to success being rigorous research, drug development, and scientific innovation. This way of thinking has pushed the organization ahead of it’s competitors and it’s flagship drug (ADCETRIS), has racked up hundreds of million in Canada and the U.S.
Dr. Clay Siegall just knows how to get things done efficiently and effectively. All in all, the future of cancer research is in great hands (via) Seattle Genetics and Dr. Siegall is steering the ship to even more success in the future.